{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:05:46Z","timestamp":1792069546660,"version":"4.4.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>R3HDM4, or R3H domain containing 4, is a gene with uncertain functions but is frequently investigated for its potential cellular roles and associations with various diseases. Kidney renal clear cell carcinoma (KIRC ), a prevalent and aggressive form of kidney cancer, currently lacks effective treatment options. This study aimed to clarify the involvement of R3HDM4 in KIRC pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>An integrated pan-cancer approach was employed to analyze data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), ArrayExpress, and the International Cancer Genome Consortium (ICGC ), systematically assessing the prognostic relevance, clinical associations, signaling pathways, DNA methylation patterns, immune infiltration profiles, and chemotherapeutic sensitivity linked to R3HDM4 expression. Bioinformatics analyses, supported by immunohistochemistry, Western blotting (WB), and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), revealed significant upregulation of R3HDM4 in KIRC tissues compared to normal controls. Kaplan\u2013Meier (KM) survival analysis indicated that elevated R3HDM4 expression correlated with poor clinical outcomes. Single-cell RNA sequencing identified cancer cells and dendritic cells as the primary sources of R3HDM4 within the KIRC tumor microenvironment. Functional assays using R3HDM4-targeting siRNA demonstrated that its depletion suppressed the proliferative, migratory, and invasive capabilities of KIRC cells. At the molecular level, R3HDM4 knockdown attenuated epithelial\u2013mesenchymal transition (EMT), as evidenced by increased E-cadherin expression and reduced levels of vimentin and matrix metalloproteinases MMP-2 and MMP-9. Comprehensive immune profiling revealed significant correlations between R3HDM4 expression and several immunological parameters, including immune cell infiltration, immune checkpoint expression, tumor mutational burden (TMB), and microsatellite instability (MSI). Notably, silencing of R3HDM4 led to increased expression of Immunoglobulin Superfamily Member 8 (IGSF8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These analyses identify R3HDM4 as a critical oncogenic driver in KIRC, potentially acting through two mechanisms: promoting tumor growth and metastasis while also exerting immunomodulatory effects, possibly mediated by IGSF8. This suggests a potential role for IGSF8 in regulating immune checkpoints, though this remains speculative. These findings highlight R3HDM4\u2019s potential as both a prognostic biomarker and a therapeutic target in KIRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1722358","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:07Z","timestamp":1763534287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["R3HDM4 influences kidney renal clear cell carcinoma progression, immune modulation, and potential links to the IGSF8 immune checkpoint"],"prefix":"10.3389","volume":"16","author":[{"given":"Kai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-run","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.3390\/cancers16234034","article-title":"The current state of the diagnoses and treatments for clear cell renal cell carcinoma","volume":"16","author":"Quinn","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: A review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01911-x","article-title":"Evolution of cell therapy for renal cell carcinoma","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/cancers15030665","article-title":"Clear cell renal cell carcinoma: from biology to treatment","volume":"15","author":"Kase","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40265-016-0665-1","article-title":"Recent advances in the medical treatment of recurrent or metastatic renal cell cancer","volume":"77","author":"Kumbla","year":"2017","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated european association of urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated european association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3390\/cancers16112092","article-title":"Immunotherapy of clear-cell renal-cell carcinoma","volume":"16","author":"Grigolo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108900","article-title":"Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review","volume":"110","author":"Liu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab056","article-title":"First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape","volume":"27","author":"Gulati","year":"2022","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.07.009","article-title":"Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma","volume":"70","author":"Atkins","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.027942","article-title":"Review and prospect of immune checkpoint blockade therapy represented by PD-1\/PD-L1 in the treatment of clear cell renal cell carcinoma","volume":"31","author":"Ge","year":"2023","journal-title":"Oncol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/ijms26010265","article-title":"Innovative therapies targeting drug-resistant biomarkers in metastatic clear cell renal cell carcinoma (ccRCC)","volume":"26","author":"Abah","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23700","article-title":"EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt\/FOXO3a pathway","volume":"63","author":"Zhou","year":"2024","journal-title":"Mol Carcinog"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117247","article-title":"Synthesis and biological assessment of BUB1B inhibitors for the treatment of clear cell renal cell carcinoma","volume":"285","author":"El Hafi","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"oyae276","DOI":"10.1093\/oncolo\/oyae276","article-title":"Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma","volume":"30","author":"Choi","year":"2025","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-2836(02)01381-5","article-title":"Solution structure of the R3H domain from human Smubp-2","volume":"326","author":"Liepinsh","year":"2003","journal-title":"J Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1069","article-title":"The expression of Rpb10, a small subunit common to RNA polymerases, is modulated by the R3H domain-containing Rbs1 protein and the Upf1 helicase","volume":"48","author":"Cie\u015bla","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.06.139","article-title":"The R3H domain stabilizes poly(A)-specific ribonuclease by stabilizing the RRM domain","volume":"360","author":"Liu","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/genes16070793","article-title":"A genome-wide association study of anti-m\u00fcllerian hormone (AMH) levels in Samoan women","volume":"16","author":"Erdogan-Yildirim","year":"2025","journal-title":"Genes (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets\u2013update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3791\/62528","article-title":"Three differential expression analysis methods for RNA sequencing: limma, edgeR, DESeq2","volume":"175","author":"Liu","year":"2021","journal-title":"J Vis Exp"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","article-title":"Time-dependent ROC curve analysis in medical research: current methods and applications","volume":"17","author":"Kamarudin","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","article-title":"The Gene Ontology Resource: 20 years and still GOing strong","volume":"47","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"D1004","DOI":"10.1093\/nar\/gkab972","article-title":"EWAS Open Platform: integrated data, knowledge and toolkit for epigenome-wide association study","volume":"50","author":"Xiong","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13072-019-0316-3","article-title":"The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization","volume":"12","author":"Li","year":"2019","journal-title":"Epigenet Chromatin"},{"key":"B33","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","article-title":"TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment","volume":"51","author":"Han","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.922195","article-title":"A novel immune-related gene signature to identify the tumor microenvironment and prognose disease among patients with oral squamous cell carcinoma patients using ssGSEA: A bioinformatics and biological validation study","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1242\/jcs.100115","article-title":"E-cadherin-integrin crosstalk in cancer invasion and metastasis","volume":"126","author":"Canel","year":"2013","journal-title":"J Cell Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.024","article-title":"EMT: matter of life or death","volume":"164","author":"Gupta","year":"2016","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27","author":"Roy","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:08Z","timestamp":1763534288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1722358"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1722358","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1722358"}}